Adial Q2 Loss Per Share Misses by 10x on $46M Acquisition Charge
ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.1× avg).
Summary
Adial reported a Q2 net loss of $52M, or $11.25 per share, versus consensus estimates of $2.008M and $1.03 per share. The miss was driven by a $46.2M non-cash charge for acquired in-process R&D from the Azora Therapeutics acquisition, plus merger-related costs and severance. This follows the 10-Q filed August 14 that already disclosed a $52M quarterly loss and material weakness, but today's release adds the consensus comparison and forward guidance. Management expects to file an IND for AT177 in H1 2027 and start a Phase 1a trial in H2 2027, with cash runway into H2 2027. The stock closed at $3.98 on August 14, and the median analyst price target is $8.00.
At the time of this announcement, ADIL was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.31 to $10.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.